Nemaura Medical to Present at the LD Micro Main Event Conference
Nemaura Medical (NASDAQ: NMRD) has announced that CEO Faz Chowdhury, Ph.D., will present virtually at the 14th Annual LD Micro Main Event Conference on October 13 at 10:00 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nemaura Medical (NASDAQ: NMRD) has announced that CEO Faz Chowdhury, Ph.D., will present virtually at the 14th Annual LD Micro Main Event Conference on October 13 at 10:00 AM ET. The presentation aims to provide insights into Nemaura's advancements in non-invasive wearable diagnostic devices, including the sugarBEAT® and proBEAT™ products. Nemaura operates within the rapidly expanding global Type 2 diabetes and wearable health-tech markets, which are projected to reach substantial valuations in coming years.
Details
News Market Reaction – NMRD
The recorded move for NMRD in the trading session of this news was +1.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Loughborough, England, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will be presenting virtually at the 14th Annual LD Micro Main Event Conference.
Dr. Chowdhury will deliver his corporate presentation on October 13 at 10:00 AM ET.
Register to watch the presentation here.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.